quinidine has been researched along with paroxetine in 28 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (14.29) | 18.2507 |
2000's | 8 (28.57) | 29.6817 |
2010's | 15 (53.57) | 24.3611 |
2020's | 1 (3.57) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Colado, MI; Green, AR; Williams, JL | 1 |
Belpaire, FM; Brøsen, K; Rasmussen, BB; Temmerman, A; Wijnant, P | 1 |
Clement, EM; Elliott, JM; Grahame-Smith, DG | 1 |
Lurcott, G | 1 |
Bertelsen, KM; Greenblatt, DJ; Obach, RS; Venkatakrishnan, K; Von Moltke, LL | 1 |
Katoh, M; Nakajima, M; Sawada, T; Soeno, Y; Tateno, C; Yokoi, T; Yoshizato, K | 1 |
Castberg, I; Davies, SJ; Lennard, MS; Lewis, G; Spigset, O; Taylor, S; Westin, AA | 1 |
Pope, LE; Schoedel, KA; Sellers, EM | 1 |
Achanti, S; Katta, RR | 1 |
Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S | 1 |
Ahemad, N; Dong, AN; Ong, CE; Palanisamy, UD; Pan, Y; Yiap, BC | 1 |
2 review(s) available for quinidine and paroxetine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone.
Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Binding, Competitive; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Fluoxetine; Humans; Hydrocodone; Oxycodone; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors | 1998 |
1 trial(s) available for quinidine and paroxetine
Article | Year |
---|---|
Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
Topics: Adult; Affective Symptoms; Dextromethorphan; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Paroxetine; Quinidine | 2012 |
25 other study(ies) available for quinidine and paroxetine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Inhibition of P-glycoprotein by newer antidepressants.
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Body Temperature Regulation; Brain; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Female; Fever; Humans; Hydroxyindoleacetic Acid; Male; Mixed Function Oxygenases; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Phenotype; Proadifen; Quinidine; Rats; Rectum; Serotonin; Serotonin Agents; Sex Factors; Tritium | 1995 |
The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Anti-Arrhythmia Agents; Child; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Kinetics; Male; Methylation; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Investigation of the presynaptic effects of quinine and quinidine on the release and uptake of monoamines in rat brain tissue.
Topics: Animals; Biogenic Monoamines; Brain; Dopamine; In Vitro Techniques; Male; Nerve Tissue Proteins; Norepinephrine; Paroxetine; Presynaptic Terminals; Quinidine; Quinine; Rats; Rats, Sprague-Dawley; Serotonin; Synaptosomes | 1998 |
Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoxetine; Humans; Microsomes, Liver; Paroxetine; Quinidine | 2003 |
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.
Topics: Adrenergic Agents; Animals; Chimera; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Interactions; Humans; Infant; Liver; Male; Mice; Mice, SCID; Models, Animal; Paroxetine; Quinidine; Urokinase-Type Plasminogen Activator | 2007 |
Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies.
Topics: Adult; Antidepressive Agents, Second-Generation; Antifungal Agents; Antimalarials; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Clopenthixol; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Female; Fluoxetine; Humans; In Vitro Techniques; Ketoconazole; Male; Methotrimeprazine; Microsomes, Liver; Middle Aged; Paroxetine; Quinidine | 2010 |
High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study.
Topics: Animals; Chromatography, Liquid; Paroxetine; Quinidine; Rats; Reproducibility of Results; Tandem Mass Spectrometry | 2016 |
Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.
Topics: Ciprofloxacin; Clarithromycin; Computer Simulation; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Fluconazole; Humans; Itraconazole; Ketoconazole; Models, Biological; Paroxetine; Quinidine; Rifampin; Software | 2018 |
Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.
Topics: Alleles; Catalysis; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Fluoxetine; Ligands; Molecular Docking Simulation; Paroxetine; Quinidine; Terbinafine | 2022 |